IP Library › Granted Patent US 11,571,422
Granted Patent B2
US 11,571,422 · App. 17/494,517 · Granted Feb 7, 2023

Composition including rilpivirine and method for treating tumors or cancer

Inventors: Wai Yip Thomas Lee (Hong Kong, HK); Chung Sing Daniel Poon (Hong Kong, HK); Ka Lun Lai (Hong Kong, HK); Junzhe Huang (Hong Kong, HK); Ho Yin Li (Hong Kong, HK)
Assignee: SCIPIO LIFE SCIENCES LIMITED
A61K31/505A61K45/06A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,571,422
App. No.
17/494,517
Granted
Feb 7, 2023
Kind
B2
Abstract

The present invention provides a composition and method for preventing the growth of and/or treating cancerous tumors and/or delaying onset of cancer from tumor-initiating cells. The composition includes an effective amount of a compound of Formula (I) or Formula (II): or any pharmaceutically acceptable salt thereof. The composition is administered alone or in combination with one or more chemotherapeutic agents, biological agents and/or anticancer agents. The method may include administering the composition of the present invention with or without the chemotherapeutic, biological, or other cancer treatment agent to a subject in need thereof intravenously, parenterally, nasally, topically or locally, orally, or by liposome, implant or via vessel-targeted nanosuspension delivery.

Claims (24)

1. A method for preventing growth of and/or treating a cancerous tumor and/or delaying onset of cancer from tumor-initiating cells, the method comprising: administering a composition comprising an effective amount of a compound of Formula (I) or Formula (II):

or any pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the cancerous tumor and/or cancer is neuroblastoma.

2. The method of claim 1 , wherein said subject is a human comprising adult, juvenile, children or infants.

3. The method of claim 1 , wherein the composition is administered at least once daily.

4. The method of claim 1 , wherein the administering the composition of Formula (I) or Formula (II) is in combination with one or more chemotherapeutic agents, biological agents and/or anticancer agents, to a subject in need thereof.

5. The method of claim 4 wherein the one or more chemotherapeutic agents comprises one or more alkylating agents, anti-metabolites, antitumor antibiotics, topoisomerase inhibitors, mitotic inhibitors, steroids, and/or any mixtures thereof; and the one or more biological agents comprises one or more vaccines, cytokines, antibodies, protein and peptide drugs and/or any mixtures thereof.

6. The method of claim 5 , wherein said alkylating agents are one or more selected from cyclophosphamide, melphalan, temozolomide, carboplatin, cisplatin, and/or oxaliplatin.

7. The method of claim 5 , wherein said anti-metabolites are one or more selected from 5-fluorouracil, 6-mercaptopurine, cytarabine, gemcitabine, and/or methotrexate.

8. The method of claim 5 , wherein said antitumor antibiotics are one or more selected from actinomycin-D, bleomycin, daunorubicin, and/or doxorubicin.

9. The method of claim 5 , wherein said topoisomerase inhibitors are one or more selected from etoposide, irinotecan, teniposide, and/or topotecan.

10. The method of claim 5 , wherein said mitotic inhibitors are one or more selected from docetaxel, estramustine, paclitaxel, vincristine, and/or vinblastine.

11. The method of claim 5 , wherein said steroids are one or more selected from prednisone, methylprednisolone, and/or dexamethasone.

12. The method of claim 5 , wherein said antibodies are one or more selected from Hu3F8, hu14.18K322A, Hu14.18-IL-2, and/or dinutuximab.

13. A composition for preventing growth of and/or treating a cancerous tumor and/or delaying onset of cancer from tumor-initiating cells, the composition comprising: an effective amount of a compound of Formula (I) or Formula (II):

or any pharmaceutically acceptable salt thereof, the composition further including one or more

antitumor antibiotics selected from one or more of actinomycin-D, bleomycin, daunorubicin, and/or doxorubicin;

topoisomerase inhibitors selected from one or more of etoposide, irinotecan, teniposide, and/or topotecan;

mitotic inhibitors selected from one or more of docetaxel, estramustine, paclitaxel, vincristine, and/or vinblastine;

steroids selected from one or more of prednisone, methylprednisolone, and/or dexamethasone; and/or

antibodies selected from one or more of Hu3F8, hu14.18K322A, Hu14.18-IL-2, and/or dinutuximab; and

wherein the cancerous tumour and/or cancer is neuroblastoma.

14. The composition of claim 13 , further comprising one or more alkylating agents selected from cyclophosphamide, melphalan, temozolomide, carboplatin, cisplatin, and/or oxaliplatin.

15. The composition of claim 13 , further comprising one or more anti-metabolites selected from 5-fluorouracil, 6-mercaptopurine, cytarabine, gemcitabine, and/or methotrexate.

16. The composition of claim 13 , wherein said composition is formulated into one or more of the following administrative forms: a parenteral formulation, an aqueous solution, a liposome, an injectable solution, an injectable suspension, an intravenous solution, an intravenous suspension/nanosuspension, a tablet, a pill, a lozenge, a capsule, a caplet, a patch, a spray, an inhalant, a powder, a freeze-dried powder, a patch, a gel, a geltab, a suspension, a nanosuspension, a microparticle, a nanoparticle, a nanoliposome, a microgel, a pellet, a suppository, an oral suspension, an oral disintegrating tablet, an oral dispersible tablet, an oral disintegrating film, a microemulsion, a nanoemulsion and a self-emulsifying drug delivery system and/or any combination thereof.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 25, 2023
From: SCIPIO LIFE SCIENCES LIMITED
To: APTORUM THERAPEUTICS LIMITED
Reel/Frame 064706/0587 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2022
From: APTORUM THERAPEUTICS LIMITED
To: SCIPIO LIFE SCIENCES LIMITED
Reel/Frame 058668/0542 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 6, 2021
From: LEE, WAI YIP THOMAS; POON, CHUNG SING DANIEL; LAI, KA LUN; HUANG, JUNZHE; LI, HO YIN
To: APTORUM THERAPEUTICS LIMITED
Reel/Frame 057714/0842 →
Continuity (4)
Continuation 17105879 · Nov 27, 2020
Provisional Application 63072281 · Aug 31, 2020
Provisional Application 62941891 · Nov 29, 2019
Related Publication 20220023297A1 · Jan 27, 2022